FAM
BPMC

Fred Alger Management’s Blueprint Medicines BPMC Stock Holding History

Fred Alger Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,681
Closed -$2.27M – 445
2025
Q1 		$2.27M Buy
25,681
+58
+0.2% +$5.66K 0.01% 291
2024
Q4 		$2.23M Sell
25,623
-7,487
-23% -$686K 0.01% 321
2024
Q3 		$3.06M Sell
33,110
-15,478
-32% -$1.54M 0.01% 291
2024
Q2 		$5.24M Buy
48,588
+31,675
+187% +$3.17M 0.03% 239
2024
Q1 		$1.6M Buy
+16,913
New +$1.45M 0.01% 356
2018
Q4 		– Sell
-8,000
Closed -$624K – 521
2018
Q3 		$624K Sell
8,000
-500
-6% -$34.8K ﹤0.01% 345
2018
Q2 		$540K Buy
8,500
+3,000
+55% +$239K ﹤0.01% 356
2018
Q1 		$504K Buy
+5,500
New +$474K ﹤0.01% 370
2017
Q4 		– Sell
-8,000
Closed -$557K – 564
2017
Q3 		$557K Buy
8,000
+4,000
+100% +$214K ﹤0.01% 350
2017
Q2 		$203K Buy
+4,000
New +$170K ﹤0.01% 390

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fred Alger Management's BPMC Position: Q2 2025 in Review

Fred Alger Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 25,681 shares — an estimated $2.27M sold.

Fred Alger Management first reported a position in BPMC in Q2 2017 and held it in 10 quarters. The position peaked at $5.24M in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Fred Alger Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Fred Alger Management sold 25,681 Blueprint Medicines shares in Q2 2025, an estimated $2.27M.
  • Fred Alger Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 10 quarters.
  • Fred Alger Management's Blueprint Medicines position peaked at $5.24M in Q2 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Fred Alger Management's 13F filing for Q2 2025, filed 14 Aug 2025.